Invion (ASX:IVX) confirms significant improvement in efficacy when ICI is used with drug INV043 – The Market Herald

Subscribe

Be the first with news that moves the market

  • Invion (IVX) confirms that combination therapy of INV043 and immune checkpoint inhibitors (ICI) is more effective than single ICI therapy in its latest proof-of-concept (PoC) study
  • The findings come from Invion’s third PoC study undertaken by its research partner, the Hudson Medical Research Institute, with results showing an approximately 65% ​​reduction in tumor size in mice with triple negative breast cancer (TNBC)
  • It also shows clear tumor stabilization and regression despite a restricted treatment protocol and the tumors were also significantly smaller than those in mice given monotherapy.
  • The results open up partnership opportunities, as INV043 may offer pharmaceutical companies with ICI drugs the potential to improve clinical outcomes, develop new intellectual property and extend the patent life of their ICI therapies.
  • IVX shares hold at 1.3 cents at 10:41 a.m. AEST

Invion (IVX) has confirmed that a combination therapy of its lead drug INV043 and immune checkpoint inhibitors (ICI) is more effective than stand-alone ICI therapy in its latest proof-of-concept (PoC) study.

The findings come from the company’s third PoC study undertaken by its research partner, the Hudson Medical Research Institute.

This PoC was specifically designed to assess whether INV043 can be used in combination with PD-1-targeting immune checkpoint inhibition to improve outcomes in mice with triple-negative breast cancer (TNBC).

The results showed an approximately 65% ​​reduction in tumor size in mice with TNBC.

It also showed clear tumor stabilization and regression despite a restricted treatment protocol and the tumors were also significantly smaller than those in mice given monotherapy.

Research group leader, Ovarian Cancer Biomarkers at the Hudson Institute, Dr. Andrew Stephens concluded that the results provide compelling rationale for the combination therapy.

“As INV043 induces both direct cell death in the tumor microenvironment and
as well as the release of tumor neoantigens, we hypothesized that INV043 would combine with checkpoint inhibition to improve antitumor efficacy compared to either monotherapies alone” , said Dr. Stephens.

Unlike previous PoC studies, delivery was limited to a small portion of the tumor to specifically probe combination approach and immune-mediated changes after therapy in an animal model.

These results also open up partnership opportunities as INV043 may offer pharmaceutical companies with ICI drugs the potential to improve clinical outcomes, develop new intellectual properties and extend the patent life of their ICI therapies.

IVX shares were flat at 1.3 cents as of 10:41 a.m. AEST.

Sara H. Byrd